PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.3 MILLION PRIVATE PLACEMENT Paris, July 1st, 2026, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors (the “Private Placement”). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the “AMF”). Use of proceeds The Company intends to use the net proceeds of the Private Placement to finance research and development programs of the Company, the priority being the AB8939 program in acute myeloid leukemia and the masitinib in amyotrophic lateral sclerosis. This transaction strengthens the Company’s...

Press ReleaseNicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone PaymentNCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) by exclusive licensee Kowa Company, Ltd. (Kowa) for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension €3 million milestone payment due to Nicox, with a further milestone payment due upon approval Submission based on positive results from two Phase 3 clinical trials, Mont Blanc and Denali NCX 470 is exclusively licensed to Ocumension Therapeutics for the Chinese market, South Korea and Southeast Asia and to Kowa for Japan and the rest of the worldJuly 1st, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124,...

Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the “Investors” page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi’s Q2 2026 results will be published on July 30, 2026. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team...

More information is available on Aedifica’s website via the link below and can be accessed subject to the usual restrictions.Press release EN Communiqué de presse FR Persbericht NL

Regulated information Nyrstar NV – Results of the annual and extraordinary general shareholders’ meetings held on 30 June 2026 30 June 2026 at 7:00 CET Nyrstar NV (the “Company”) held its annual general shareholders’ meeting (“AGM”) and an extraordinary general shareholders’ meeting (“EGM”) in Brussels yesterday. The AGM did not have an attendance quorum requirement for the items on the agenda. The shareholders’ meeting approved all items on the agenda of the AGM. The attendance quorum required for the items on the agenda of the EGM was not met. The Board will consider in due time whether and when it will hold a second EGM to deliberate on this item. About Nyrstar NV The Company is incorporated in Belgium and listed on Euronext Brussels under the symbol NYR. For further information please visit the...

Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases Pratteln, Switzerland, July 1, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes topline results from a two-part Phase 1 clinical study of AGAMREE® conducted by its North American licensing partner, Catalyst Pharmaceuticals, Inc. (“Catalyst”). The study suggests that AGAMREE® delivers glucocorticoid and anti-inflammatory activity, while avoiding significant immunosuppressive effects, supporting its potential use as a treatment across a broad range of chronic inflammatory rare diseases. The study, conducted in healthy adult volunteers, evaluated equipotency between deflazacort and AGAMREE® and assessed the clinical immunosuppressive potential of AGAMREE® across ascending doses. In part A, both AGAMREE® and deflazacort...

State authority initiates public commenting phase following positive human health assessment, marking key step toward potential state registration Ghent, BELGIUM, July 01, 2026 (GLOBE NEWSWIRE) —             Press Release Biotalys (Euronext Brussels: BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, today announces further progress in the regulatory review process of its first biofungicide, EVOCA®, in the United States. The California Department of Pesticide Regulation (CDPR), Pesticide Registration Branch, has now initiated the public consultation phase of the EVOCA dossier, marking an important step forward in the evaluation process. This milestone follows the recommendation by CDPR’s Human Health Assessment Branch, which concluded that the data and...

Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Roland Wandeler as CEO – effective October 1, 2026 – an experienced biopharmaceutical executive combining scientific expertise with business acumen to translate innovation into performance and lead Idorsia’s next phase of growth Allschwil, Switzerland – July 1, 2026Idorsia Ltd (SIX: IDIA) today announced the appointment of Roland Wandeler, PhD, as Chief Executive Officer (CEO), effective October 1, 2026. The appointment comes at a pivotal stage for Idorsia, as the company continues to execute its strategy to accelerate growth and unlock the full value of its innovative portfolio. Roland Wandeler will succeed Jean-Paul Clozel, MD, who has been serving as ad-interim CEO since March 2026 and will continue in his role as Chairman of the Board of Directors. Jean-Paul Clozel will remain...